여성 암 환자의 가임력 보존
Fertility Preservation in Female Cancer Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Recent anticancer treatments have led to significant reduction in mortality, but also to an increase in unwanted side effects such as loss of fertility. Combined with an increased age for childbearing, a higher number of cancer survivors require fertility preservation to be pregnant after cancer treatment. The threat of cancer treatment-related infertility can lead to psychological distress, and many patients are interested in maintaining fertility and future pregnancy at the time of cancer diagnosis. International guidelines recommend that physicians discuss, as early as possible, with all patients of reproductive age their risk of infertility from the disease and/or treatment and inform fertility preservation options. Embryo/oocyte cryopreservation are standard strategies for fertility preservation in female patients. Another strategy is pharmacological protection with gonadotropin releasing hormone agonist (GnRH agonist). Ovarian tissue cryopreservation is still considered experimental techniques. In the present manuscript, we summarize and discuss the up-to-date knowledge on fertility preservation in women with cancer patients.
Abstract
Recent anticancer treatments have led to significant reduction in mortality, but also to an increase in unwanted side effects such as loss of fertility. Combined with an increased age for childbearing, a higher number of cancer survivors require fertility preservation to be pregnant after cancer treatment. The threat of cancer treatment-related infertility can lead to psychological distress, and many patients are interested in maintaining fertility and future pregnancy at the time of cancer diagnosis. International guidelines recommend that physicians discuss, as early as possible, with all patients of reproductive age their risk of infertility from the disease and/or treatment and inform fertility preservation options. Embryo/oocyte cryopreservation are standard strategies for fertility preservation in female patients. Another strategy is pharmacological protection with gonadotropin releasing hormone agonist (GnRH agonist). Ovarian tissue cryopreservation is still considered experimental techniques. In the present manuscript, we summarize and discuss the up-to-date knowledge on fertility preservation in women with cancer patients.
참고문헌 (35)
- Schover LR, "Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors:a review", Med Pediatr Oncol, 33(1), pp.53~59 (1999)
- Schover LR, "Having children after cancer. A pilot survey of survivors’attitudes and experiences", Cancer, 86(4), pp.697~709 (1999)
- Duffy C, "Medical and psychosocial aspects of fertility after cancer", Cancer J, 15(1), pp.27~33 (2009)
- Rosen A, "Psychosocial distress in young cancer survivors", Semin Oncol Nurs, 25(4), pp.268~277 (2009)
- Howard-Anderson J, "Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review", J Natl Cancer Inst, 104(5), pp.386~405 (2012)
- Partridge AH, "Webbased survey of fertility issues in young women with breast cancer", J Clin Oncol, 22(20), pp.4174~4183 (2004)
- Loren AW, "American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update", J Clin Oncol, 31(19), pp.2500~2510 (2013)
- Broekmans FJ, "Ovarian aging:mechanisms and clinical consequences", Endocr Rev, 30(5), pp.465~493 (2009)
- Faddy MJ, "Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause", Hum Reprod, 7(10), pp.1342~1346 (1992)
- Nelson SM., "Biomarkers of ovarian response: current and future applications", Fertil Steril, 15(99(4)), pp.963~969 (2013)
- Ben-Aharon I, "What lies behind chemotherapy-induced ovarian toxicity?", Reproduction, 144(2), pp.153~163 (2012)
- Meirow D, "Toxicity of chemotherapy and radiation on female reproduction", Clin Obstet Gynecol, 53(4), pp.727~739 (2010)
- Sullivan SD, "Insights into primary ovarian insufficiency through genetically ngineered mouse models", Semin Reprod Med, 29(4), pp.283~298 (2011)
- Kalich-Philosoph L1, "Cyclophosphamide triggers follicle activation and "burnout";AS101 prevents follicle loss and preserves fertility", Sci Transl Med, 5(185), pp.185ra62~ (2013)
- Roness H, "Ovarian follicle burnout: a universal phenomenon?", Cell Cycle, 12(20), pp.3245~3246 (2013)
- Fleischer RT, "The effects of chemotherapy and radiotherapy on fertility in premenopausal women", Obstet Gynecol Surv, 66(4), pp.248~254 (2011)
- Gosden RG, "Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary", Hum Reprod, 12(11), pp.2483~2488 (1997)
- Speiser B, "Aspermia following lower truncal irradiation in Hodgkin’s disease", Cancer, 32(3), pp.692~698 (1973)
- Rodriguez-Wallberg KA, "Fertility preservation medicine: options for young adults and children with cancer", J Pediatr Hematol Oncol, 32(5), pp.390~396 (2010)
- Goldfarb SB, "Fertility Preservation for the Young Breast Cancer Patient", Ann Surg Oncol, 23(5), pp.1530~1536 (2016)
- Gubbala K, "Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis", J Ovarian Res, 7, pp.69~79 (2014)
- von Wolff M1, "Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase", Fertil Steril, 92(4), pp.1360~1365 (2009)
- Sönmezer M, "Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles", Fertil Steril, 95(6), pp.2125.e9~2125.e11 (2011)
- Marrs RP, "Potential factors affecting embryo survival and clinical outcome with cryopreserved pronuclear human embryos", Am J Obstet Gynecol, 190(6), pp.1766~1771 (2004)
- Dahhan T1, "Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction", Cochrane Database Syst Rev, 8(11), pp.CD010240~ (2013)
- Balkenende EM, "A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen", Hum Reprod, 28(4), pp.953~959 (2013)
- Oktay K, "Fertility preservation in breast cancer patients:a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation", J Clin Oncol, 23(19), pp.4347~4353 (2005)
- Noyes N, "Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies", Reprod Biomed Online, 18(6), pp.769~776 (2009)
- Rodriguez-Wallberg KA, "Lundqvist ML, Hovatta O. Cryopreservation of oocytes and gonadal tissue in a large fertility preservation programme at a teaching hospital", Hum Reprod, 25(Suppl 1), pp.i104~ (2010)
- Bedaiwy MA, "Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis", Fertil Steril, 95(3), pp.906-14.e1~906-14.e4 (2011)
- Moore HC, "POEMS", S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy, 2015, pp.372(10), 923~932
- Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology, "Mature oocyte cryopreservation:a guideline", Fertil Steril, 99(1), pp.37~43 (2013)
- Oktay K1, "Embryo development after heterotopic transplantation of cryopreserved ovarian tissue", Lancet, 363(9412), pp.837~840 (2004)
- Sonmezer M, "Orthotopic and heterotopic ovarian tissue transplantation", Best Pract Res Clin Obstet Gynaecol, 24(1), pp.113~126 (2010)
- Donnez J, "Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation", Fertil Steril, 99(6), pp.1503~1513 (2013)